Answered

Which of the following PD-1/PD-L1 inhibitors are approved by the FDA for the treatment of patients with advanced NSCLC?

A. Pembrolizumab, nivolumab, atezolizumab, durvalumab
B. Pembrolizumab, nivolumab, durvalumab
C. Pembrolizumab, nivolumab, atezolizumab, durvalumab, cemiplimab
D. Pembrolizumab, nivolumab, atezolizumab, durvalumab, avelumab



Answer :

GinnyAnswer

Final answer:

Pembrolizumab, nivolumab, and durvalumab are FDA-approved PD-1/PD-L1 inhibitors for advanced NSCLC treatment.


Explanation:

Pembrolizumab, nivolumab, durvalumab are approved by the FDA for the treatment of patients with advanced NSCLC. These drugs are PD-1/PD-L1 inhibitors that have shown efficacy in clinical trials for treating non-small cell lung cancer.


Learn more about Immunotherapy for NSCLC treatment here:

https://brainly.com/question/32076987


Other Questions